Ad5-nCoV is being developed by China's CanSino Biologics Inc.Current status: Based on phase II trial results of Ad5-nCoV, the vaccine was approved by China’s Health Bureau of the Logistics Support Department of the Central Military Commission on June 25, for military use for one year.Mode of Action: Ad5-nCoV is a genetically engineered vaccine that contains replication-defective adenovirus type 5 virus as a vector, expressing the spike glycoprotein of SARS-CoV-2. The vaccination will help in generating neutralizing antibodies against live SARS-CoV-2, thereby rendering a person immune.Next Milestone: Preparations of commencing Phase III studies of Ad5-nCoV in China, Brazil are underway.Researchers are also planning to start phase III trials of the vaccine in Canada this fall, according to reports.